A Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effects on Heterotopic Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva

Trial Profile

A Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effects on Heterotopic Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2018

At a glance

  • Drugs Garetosmab (Primary)
  • Indications Fibrodysplasia ossificans progressiva
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LUMINA-1
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 27 Apr 2018 Planned End Date changed from 14 May 2020 to 4 Aug 2020.
    • 27 Apr 2018 Planned primary completion date changed from 12 Jun 2019 to 3 Sep 2019.
    • 16 Nov 2017 Planned End Date changed from 9 Apr 2020 to 14 May 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top